A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...

Participation in the 340B Drug Pricing Program does not increase the use of targeted therapy in older patients with advanced prostate cancer, a study suggests.

Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success ...

Francis Medical Inc., a Twin Cities med-tech manufacturer that's developing a way to treat prostrate and other cancers with water vapor, said Tuesday it raised $80 million in its latest equity funding ...

BNT-325 is under clinical development by BioNTech and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC).

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...

New research from the IU School of Medicine found a discovery that could lead to new treatments for prostate cancer. The ...

Precision Drug Olaparib May Be Effective Without Hormone Therapy for Some Men With Biochemically Recurrent Prostate Cancer Aug. 22, 2024 — The anti-cancer drug olaparib may be effective in ...

they may also look to complementary or alternative medicine for help managing the symptoms and side effects of their prostate cancer treatment. “Chemotherapy and surgery and drug therapies all ...

Prostate cancer, especially in advanced stages such ... Cisplatin, a widely used anticancer drug, has been used in combination therapies but its use is limited by severe side effects, including ...

Prostate cancer hijacks the normal prostate's growth ... paves the way for new diagnostic tests to guide treatment and could also help drug developers identify novel ways to stop the disease.

Metformin, a drug for type 2 diabetes ... a natural substance that controls the amount of glucose in the blood. Prostate cancer is the number one cancer in Nigerian men and constitutes 11 percent ...